Bottom line
IYH vs IXJ: the short answer
IYH (iShares U.S. Healthcare ETF) and IXJ (iShares Global Healthcare ETF) share a meaningful slice of their top holdings — about 74% by weight.
IYH is cheaper at 0.37% vs 0.38% — a difference of $1.00 a year per $10,000 invested.
Over five years, IYH returned +7.0% a year vs +6.4% for IXJ.
Updated Nov 19, 2026
IYH vs IXJ side by side
| IYH | IXJ | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | iShares | iShares |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.37% | 0.38% |
| Annual cost per $10k | $37 | $38 |
| 10-yr cost on $10k (prospectus) | $468 | $480 |
| Max front load | None | None |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +13.1% | +14.9% |
| 5-yr return (annualized) | +7.0% | +6.4% |
| 10-yr return (annualized) | +9.4% | +8.2% |
| Best quarter | +15.3% | +13.6% |
| Worst quarter | −12.7% | −11.8% |
| Net assets (fund) | $3.6B | $3.8B |
| Number of holdings | 103 | 124 |
| Portfolio turnover | 3% | 2% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | IYH | IXJ | Difference |
|---|---|---|---|
| 2025 | +13.1% | +14.9% | −1.7% |
| 2024 | +3.1% | +0.6% | +2.5% |
| 2023 | +2.1% | +3.5% | −1.4% |
| 2022 | −4.4% | −4.7% | +0.3% |
| 2021 | +23.4% | +19.5% | +3.9% |
| 2020 | +15.5% | +12.5% | +3.0% |
| 2019 | +20.8% | +23.4% | −2.5% |
| 2018 | +5.9% | +2.9% | +3.0% |
| 2017 | +22.3% | +20.3% | +2.0% |
| 2016 | −2.8% | −6.2% | +3.4% |
Source: Fund prospectus bar charts
Holdings overlap
17 of IYH's top 25 holdings also appear in IXJ's top 25.
| Holding | IYH | IXJ |
|---|---|---|
| Eli Lilly And Company | 15.11% | 10.93% |
| Johnson & Johnson | 10.17% | 7.04% |
| Abbvie Inc. | 7.32% | 5.12% |
| Unitedhealth Group Incorporated | 6.16% | 4.40% |
| Merck & Co., Inc. | 5.31% | 4.12% |
| Thermo Fisher Scientific Incorporated | 3.52% | 2.42% |
| Amgen Inc. | 3.42% | 2.54% |
| Abbott Laboratories | 3.02% | 2.05% |
| Gilead Sciences, Inc. | 2.66% | 2.04% |
| Pfizer Inc. | 2.35% | 1.78% |
| Bristol-myers Squibb Company | 2.20% | 1.53% |
| Intuitive Surgical, Inc. | 2.05% | 1.83% |
| Danaher Corporation | 2.03% | 1.56% |
| Vertex Pharmaceuticals Incorporated | 2.00% | 1.64% |
| Stryker Corporation | 1.86% | 1.41% |
Source: SEC Form N-PORT
IYH top 10
- Eli Lilly And Company — 15.11%
- Johnson & Johnson — 10.17%
- Abbvie Inc. — 7.32%
- Unitedhealth Group Incorporated — 6.16%
- Merck & Co., Inc. — 5.31%
- Thermo Fisher Scientific Incorporated — 3.52%
- Amgen Inc. — 3.42%
- Abbott Laboratories — 3.02%
- Gilead Sciences, Inc. — 2.66%
- Pfizer Inc. — 2.35%
IXJ top 10
- Eli Lilly And Company — 10.93%
- Johnson & Johnson — 7.04%
- Abbvie Inc. — 5.12%
- Unitedhealth Group Incorporated — 4.40%
- Merck & Co., Inc. — 4.12%
- Astrazeneca Plc — 3.76%
- Roche Holding AG — 3.75%
- Novartis AG — 3.71%
- Amgen Inc. — 2.54%
- Thermo Fisher Scientific Incorporated — 2.42%
FAQ
What is the difference between IYH and IXJ?
Which is cheaper, IYH or IXJ?
Should I own both IYH and IXJ?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.